Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine and Milnacipran for Depression in Palliative Care
NCT02783430Phase 3Completed
- Sponsor
- CHU de Lille
- Start
- Sep 2016
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in major depressive disorder (MDD) comparing Milnacipran + Ketamine with Milnacipran + Placebo (2 arms). Primary endpoint: Montgomery-Åsberg Depression Rating Scale at Day 2. Started Sep 2016; status: completed.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02783430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02783430.